Background The multikinase inhibitor sorafenib inhibits angiogenesis and tumor cell
proliferation. Sorafenib targets signaling pathways involved in liver regeneration. Previous …

Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib
prolongs survival of patients with advanced disease and is approved for the systemic …

BACKGROUND: Sorafenib is currently approved for advanced hepatocellular carcinoma
(HCC) and is presently being studied as an adjuvant treatment for HCC following resection …

Background Liver regeneration is vital for the survival of patients submitted to extensive liver
resection as a treatment of hepatocellular carcinoma (HCC). Sorafenib is a multikinase …

Background Sorafenib is a multikinase inhibitor with antiangiogenic and antiproliferative
properties, approved for the treatment of hepatocellular carcinoma. The effect of S orafenib …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Background Post‐operative liver regeneration may contribute to tumor recurrence. There is
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

Background Multidrug resistance is a major reason for poor treatment results in advanced
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …